biostudies-otherUnknownAndrade VictorHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/S-ECPF-GEOD-26544EurocanPlatformIntroduction: Peri-operative window trials, using molecular biomarkers as surrogate endpoints for treatment response, offer investigators a uniqueopportunity to obtain intact tumor samples at 2 different time-points and thus evaluate potential biomarkers over a short period of time. Here we report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected after a 10-day exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared to untreated controls. Methods: Paired tumor samples (biopsy and surgical) were obtained from 26 postmenopausal women with ER-positive breast cancer. Patients were assigned anastrozole (1mg/dy) for 10 days immediately prior to surgery (13 cases) or no treatment (13 controls). 502 cancer-relabiostudies-othertranscription profiling by arrayEurocanPlatformSakr RitaPatil AsawariQin Li-XuanArroyo CrispinitaBrogi EdiMorrogh MaryOlshen AdamAndrade VictorKing TariMorrow MonicaMo QuianxingfalseDifferentially expressed genes in window trials are influenced by the wound healing process: lessons learned from a pilot study with AnastrozoleIntroduction: Peri-operative window trials, using molecular biomarkers as surrogate endpoints for treatment response, offer investigators a uniqueopportunity to obtain intact tumor samples at 2 different time-points and thus evaluate potential biomarkers over a short period of time. Here we report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected after a 10-day exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared to untreated controls. Methods: Paired tumor samples (biopsy and surgical) were obtained from 26 postmenopausal women with ER-positive breast cancer. Patients were assigned anastrozole (1mg/dy) for 10 days immediately prior to surgery (13 cases) or no treatment (13 controls). 502 cancer-rela2016-04-14T13:52:25Z2016-04-14T13:52:25Z2016-04-14T13:52:25ZS-ECPF-GEOD-26544GSE26544E-GEOD-26544EFO_0000635EFO_0000305E-GEOD-26544